Form 4: Janux Therapeutics Director Receives Stock Options and Restricted Stock Units

Director Vickie L Capps acquired stock options and restricted stock units in Janux Therapeutics, Inc.

Summary

• On June 26, 2024, Vickie L Capps, a director of Janux Therapeutics, Inc., acquired 2,500 shares of common stock in the form of restricted stock units (RSUs) and options to purchase 8,350 shares.
• The RSUs will vest on the earlier of June 26, 2025, or the date of the next annual meeting of the Issuer's stockholders, subject to continuous service.
• The stock options will vest in equal monthly installments over 12 months following June 26, 2024, but will be fully vested by the date of the next annual meeting of the Issuer's stockholders, subject to continuous service.
• Following these transactions, Capps directly owns 68,043 shares of Janux Therapeutics common stock and options to purchase 8,350 shares.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to positively as it aligns management with shareholder interests.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedules tied to continuous service incentivize the director to remain with the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the RSUs and stock options.

Industry Context

Stock options and RSU grants are common forms of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in the biotech industry to incentivize performance and align interests with shareholders, similar to companies like Amgen and Gilead Sciences.
• The vesting schedule of the options and RSUs is typical, often tied to continued service and company milestones, which is comparable to practices at Regeneron and Vertex Pharmaceuticals.

Stakeholder Impact

• The grant of equity to a director can positively impact shareholders by aligning management's interests with long-term value creation.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates